王小燕——重组人脑利钠肽对失代偿性心力衰竭患者左室射血功能与预后的影响详解.doc

重组人脑利钠肽对失代偿性心力衰竭患者左室射血功能与预后的影响 小燕河西学院甘肃省张掖734000） 摘要：目的：探讨重组人脑利钠肽对失代偿性心力衰竭患者左室射血功能与预后的影响失代偿性心力衰竭患者。用药24h观察组液体出入量差为1171.6±444.8ml，对照组出入量差为822.3±268.4ml（p＜0.05）。治疗后两组呼吸困难均有显著缓解，肺部啰音减少，周身水肿症状减轻；加用重组人脑利钠肽的观察组各症状缓解程度均显著好于常规治疗的对照组（p＜0.05）。结论：重组人脑利钠肽失代偿性心力衰竭患者左室射血功能预后重组人脑利钠肽失代偿性心力衰竭左室射血功能Effect of recombinant human brain natriuretic peptide in patients with left ventricular ejection function of decompensated heart failure and prognosis Abstract: Objective: To investigate the effects of recombinant human brain natriuretic peptide of patients with left ventricular ejection function of decompensated heart failure and prognosis. Methods: A retrospective analysis 2014.3 to hospitalized patients in our hospital during the period of the 2015.3 90 cases of decompensated heart failure patients medical records, before and after treatment in patients with cardiac function and degree of difficulty in breathing, total liquid intake and output, adverse reactions and medication for 1 month after cardiovascular events occurred situation. Results: After 72h of treatment, observation group left ventricular ejection ejection fraction and brain natriuretic peptide (BNP) level was significantly higher than that of the control group, central venous pressure was lower than that of the control group, t=2.907, 2.833, 2.915, P 0.05, suggests the existence of significant differences, was statistically significant. The difference of liquid in the 24h observation group was 1171.6 + 444.8ml, the control group was 822.3 + 268.4ml, t=2.872, P 0.05. After treatment, two groups of dyspnea significantly alleviated, reduce pulmonary rales, alleviate the symptoms of systemic edema; and observation of recombinant human brain natriuretic titanium group, the symptoms relieved degree were significantly better than conventional therapy in the control group, t=2.370, 2.016 and 2.244, P 0.05, suggesting that was statistically significant. Conclusion: Recombinant human brain natriuretic peptide can significantly